Co-Authors
This is a "connection" page, showing publications co-authored by JACK A ROTH and LIN JI.
Connection Strength
3.853
-
High throughput profiling of serum phosphoproteins/peptides using the SELDI-TOF-MS platform. Methods Mol Biol. 2012; 818:199-216.
Score: 0.409
-
Tumor suppressor FUS1 signaling pathway. J Thorac Oncol. 2008 Apr; 3(4):327-30.
Score: 0.315
-
3p21.3 tumor suppressor cluster: prospects for translational applications. Future Oncol. 2005 Feb; 1(1):79-92.
Score: 0.253
-
TUSC2 Immunogene Therapy Synergizes with Anti-PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic Kras-Mutant Mouse Lung Cancer Models. Cancer Immunol Res. 2018 02; 6(2):163-177.
Score: 0.156
-
TUSC2 downregulates PD-L1 expression in non-small cell lung cancer (NSCLC). Oncotarget. 2017 Dec 08; 8(64):107621-107629.
Score: 0.154
-
Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics. Oncotarget. 2017 Jul 18; 8(29):48222-48239.
Score: 0.150
-
TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted by the Repurposed Drug Auranofin. Sci Rep. 2016 11 15; 6:35741.
Score: 0.143
-
MicroRNA-mediated target mRNA cleavage and 3'-uridylation in human cells. Sci Rep. 2016 07 21; 6:30242.
Score: 0.140
-
Detection of siRNA-mediated target mRNA cleavage activities in human cells by a novel stem-loop array RT-PCR analysis. Biochem Biophys Rep. 2016 Jul 01; 6:16-23.
Score: 0.140
-
Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy. PLoS One. 2015; 10(6):e0123967.
Score: 0.130
-
The tumor suppressor gene TUSC2 (FUS1) sensitizes NSCLC to the AKT inhibitor MK2206 in LKB1-dependent manner. PLoS One. 2013; 8(10):e77067.
Score: 0.116
-
KEAP1-dependent synthetic lethality induced by AKT and TXNRD1 inhibitors in lung cancer. Cancer Res. 2013 Sep 01; 73(17):5532-43.
Score: 0.114
-
Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. PLoS One. 2012; 7(4):e34833.
Score: 0.105
-
Analysis of protein-protein interaction using proteinchip array-based SELDI-TOF mass spectrometry. Methods Mol Biol. 2012; 818:217-26.
Score: 0.102
-
The effect of adenovirus-mediated gene expression of FHIT in small cell lung cancer cells. Cancer Invest. 2011 Dec; 29(10):683-91.
Score: 0.102
-
Regulation of tumor suppressor gene FUS1 expression by the untranslated regions of mRNA in human lung cancer cells. Biochem Biophys Res Commun. 2011 Jul 01; 410(2):235-41.
Score: 0.098
-
STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. Cancer Res. 2011 May 15; 71(10):3658-68.
Score: 0.097
-
NPRL2 sensitizes human non-small cell lung cancer (NSCLC) cells to cisplatin treatment by regulating key components in the DNA repair pathway. PLoS One. 2010 Aug 05; 5(8):e11994.
Score: 0.093
-
High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886). Cancer Biol Ther. 2009 Nov; 8(21):2073-80.
Score: 0.088
-
Fragile histidine triad-mediated tumor suppression of lung cancer by targeting multiple components of the Ras/Rho GTPase molecular switch. Cancer Res. 2007 Nov 01; 67(21):10379-88.
Score: 0.077
-
Tumor-specific activation of human telomerase reverses transcriptase promoter activity by activating enhancer-binding protein-2beta in human lung cancer cells. J Biol Chem. 2007 Sep 07; 282(36):26460-70.
Score: 0.075
-
Tumor suppressor 101F6 and ascorbate synergistically and selectively inhibit non-small cell lung cancer growth by caspase-independent apoptosis and autophagy. Cancer Res. 2007 Jul 01; 67(13):6293-303.
Score: 0.075
-
Induction of apoptosis by tumor suppressor FHIT via death receptor signaling pathway in human lung cancer cells. Biochem Biophys Res Commun. 2007 Apr 20; 355(4):993-9.
Score: 0.073
-
Synergistic tumor suppression by coexpression of FUS1 and p53 is associated with down-regulation of murine double minute-2 and activation of the apoptotic protease-activating factor 1-dependent apoptotic pathway in human non-small cell lung cancer cells. Cancer Res. 2007 Jan 15; 67(2):709-17.
Score: 0.073
-
The 3p21.3 tumor suppressor NPRL2 plays an important role in cisplatin-induced resistance in human non-small-cell lung cancer cells. Cancer Res. 2006 Oct 01; 66(19):9682-90.
Score: 0.071
-
Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells. Cancer Res. 2004 Aug 15; 64(16):5745-52.
Score: 0.061
-
Myristoylation of the fus1 protein is required for tumor suppression in human lung cancer cells. Cancer Res. 2004 May 01; 64(9):2969-76.
Score: 0.060
-
CACNA2D2-mediated apoptosis in NSCLC cells is associated with alterations of the intracellular calcium signaling and disruption of mitochondria membrane integrity. Oncogene. 2003 Jan 30; 22(4):615-26.
Score: 0.055
-
Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo. Cancer Res. 2002 May 01; 62(9):2715-20.
Score: 0.052
-
Genetic variants in cytokine signaling pathways and clinical outcomes in early-stage lung cancer patients. J Thorac Cardiovasc Surg. 2018 06; 155(6):2635-2645.e15.
Score: 0.039
-
Serum MicroRNA-150 Predicts Prognosis for Early-Stage Non-Small Cell Lung Cancer and Promotes Tumor Cell Proliferation by Targeting Tumor Suppressor Gene SRCIN1. Clin Pharmacol Ther. 2018 06; 103(6):1061-1073.
Score: 0.038
-
Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells. Oncotarget. 2016 Jan 19; 7(3):3548-58.
Score: 0.034
-
Somatostatin receptor type 2-based reporter expression after plasmid-based in vivo gene delivery to non-small cell lung cancer. Mol Imaging. 2013 Oct; 12(7):1-10.
Score: 0.029
-
Gene silencing by gold nanoshell-mediated delivery and laser-triggered release of antisense oligonucleotide and siRNA. ACS Nano. 2012 Sep 25; 6(9):7681-91.
Score: 0.027
-
Activating enhancer-binding protein-2? nucleolar localization predicts poor survival after stage I non-small cell lung cancer resection. Ann Thorac Surg. 2011 Sep; 92(3):1044-50.
Score: 0.025
-
miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1. Mol Cancer Res. 2009 Aug; 7(8):1234-43.
Score: 0.022
-
Loss and reduction of FUS1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer. Clin Cancer Res. 2008 Jan 01; 14(1):41-7.
Score: 0.019
-
Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo. Cancer Gene Ther. 2004 Nov; 11(11):733-9.
Score: 0.016
-
Combination of TRAIL gene therapy and chemotherapy enhances antitumor and antimetastasis effects in chemosensitive and chemoresistant breast cancers. Mol Ther. 2003 Sep; 8(3):441-8.
Score: 0.014
-
A novel single tetracycline-regulative adenoviral vector for tumor-specific Bax gene expression and cell killing in vitro and in vivo. Oncogene. 2002 Jul 18; 21(31):4757-64.
Score: 0.013